Basel Medical Group (NASDAQ:BMGL) Stock Jumps 6.1% – Should You Buy?

Basel Medical Group Ltd (NASDAQ:BMGL)’s stock price shot up 6.1% during trading on Friday. The stock traded as high as $5.09 and last traded at $5.04. Approximately 1,781,612 shares changed hands during trading, an increase of 84% from the average session volume of 966,274 shares. The stock had previously closed at $4.75.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Basel Medical Group Price Performance

The company has a 50-day moving average price of $4.37 and a 200-day moving average price of $6.51.

Basel Medical Group (NASDAQ:BMGL) last announced its quarterly earnings data on Friday, October 30th. The company reported ($0.31) EPS for the quarter. The company had revenue of $3.14 million during the quarter.

Basel Medical Group Company Profile

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.